{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T19:54:18Z","timestamp":1761854058898,"version":"build-2065373602"},"reference-count":90,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,21]],"date-time":"2023-10-21T00:00:00Z","timestamp":1697846400000},"content-version":"vor","delay-in-days":50,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004324","name":"Astellas Pharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006484","name":"Vifor Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006484","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nefrolog\u00eda (English Edition)"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.nefroe.2023.10.005","type":"journal-article","created":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T02:00:14Z","timestamp":1700532014000},"page":"517-530","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Unresolved aspects in the management of renal anemia, a Delphi consensus of the Anemia Group of the S.E.N"],"prefix":"10.1016","volume":"43","author":[{"given":"Jos\u00e9","family":"Portol\u00e9s","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"Mart\u00edn-Malo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leyre","family":"Mart\u00edn-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gema","family":"Fern\u00e1ndez-Fresnedo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"De Sequera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Emilio S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Ortiz-Arduan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleix","family":"Cases","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nefroe.2023.10.005_bib0005","doi-asserted-by":"crossref","first-page":"642296","DOI":"10.3389\/fmed.2021.642296","article-title":"Anemia in chronic kidney disease: from pathophysiology and current treatments, to future agents","volume":"8","author":"Portoles","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.nefroe.2023.10.005_bib0010","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1681\/ASN.2011111078","article-title":"Mechanisms of anemia in CKD","volume":"23","author":"Babitt","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2023.10.005_bib0015","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1093\/ckj\/sfz091","article-title":"Anemia and iron deficiency among chronic kidney disease Stages 3-5ND patients in the Chronic Kidney Disease Outcomes and Practice Patterns Study: often unmeasured, variably treated","volume":"13","author":"Wong","year":"2020","journal-title":"Clin Kidney J"},{"year":"2001","series-title":"The RAND\/UCLA appropriateness method user\u2019s manual","author":"Fitch","key":"10.1016\/j.nefroe.2023.10.005_bib0020"},{"key":"10.1016\/j.nefroe.2023.10.005_bib0025","doi-asserted-by":"crossref","first-page":"47","DOI":"10.4103\/0253-7184.69003","article-title":"Formulating a researchable question: a critical step for facilitating good clinical research","volume":"31","author":"Aslam","year":"2010","journal-title":"Indian J Sex Transm Dis AIDS"},{"key":"10.1016\/j.nefroe.2023.10.005_bib0030","first-page":"288","article-title":"KDIGO clinical practice guideline for anemia in chronic kidney disease","volume":"2","author":"McMurray","year":"2012","journal-title":"Kid Int Suppl"},{"key":"10.1016\/j.nefroe.2023.10.005_bib0035","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1161\/CIRCULATIONAHA.118.030099","article-title":"Anemia and iron deficiency in heart failure: current concepts and emerging therapies","volume":"138","author":"Anand","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.nefroe.2023.10.005_bib0040","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1016\/j.ekir.2021.07.032","article-title":"Iron deficiency in CKD without concomitant anemia","volume":"6","author":"Wish","year":"2021","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.nefroe.2023.10.005_bib0045","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1159\/000499758","article-title":"Impact of transferrin saturation on all-cause mortality in patients on maintenance hemodialysis","volume":"48","author":"Sato","year":"2019","journal-title":"Blood Purif"},{"key":"10.1016\/j.nefroe.2023.10.005_bib0050","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1681\/ASN.2005040423","article-title":"Time-dependent associations between iron and mortality in hemodialysis patients","volume":"16","author":"Kalantar-Zadeh","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2023.10.005_bib0055","doi-asserted-by":"crossref","first-page":"e87231","DOI":"10.1371\/journal.pone.0087231","article-title":"The relationship of initial transferrin saturation to cardiovascular parameters and outcomes in patients initiating dialysis","volume":"9","author":"Koo","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.nefroe.2023.10.005_bib0060","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1471-2369-10-6","article-title":"The importance of iron in long-term survival of maintenance hemodialysis patients treated with epoetin-alfa and intravenous iron: analysis of 9.5 years of prospectively collected data","volume":"10","author":"Pollak","year":"2009","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.nefroe.2023.10.005_bib0065","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/ndt\/gfz192","article-title":"Prevalence, correlates and outcomes of absolute and functional iron deficiency anemia in nondialysis-dependent chronic kidney disease","volume":"36","author":"Awan","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2023.10.005_bib0070","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.kint.2019.04.029","article-title":"An increased mortality risk is associated with abnormal iron status in diabetic and non-diabetic Veterans with predialysis chronic kidney disease","volume":"96","author":"Cho","year":"2019","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2023.10.005_bib0075","doi-asserted-by":"crossref","first-page":"522","DOI":"10.2215\/CJN.15360920","article-title":"Heart failure hospitalization risk associated with iron status in veterans with CKD","volume":"16","author":"Cho","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2023.10.005_bib0080","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1111\/tri.12821","article-title":"Iron deficiency, anemia, and mortality in renal transplant recipients","volume":"29","author":"Eisenga","year":"2016","journal-title":"Transpl Int"},{"key":"10.1016\/j.nefroe.2023.10.005_bib0085","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1186\/s12882-018-1021-3","article-title":"Association of different iron deficiency cutoffs with adverse outcomes in chronic kidney disease","volume":"19","author":"Eisenga","year":"2018","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.nefroe.2023.10.005_bib0090","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1681\/ASN.2016121350","article-title":"C-terminal fibroblast growth factor 23, iron deficiency, and mortality in renal transplant recipients","volume":"28","author":"Eisenga","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2023.10.005_bib0095","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1681\/ASN.2020101531","article-title":"Serum biomarkers of iron stores are associated with increased risk of all-cause mortality and cardiovascular events in nondialysis CKD patients, with or without anemia","volume":"32","author":"Guedes","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2023.10.005_bib0100","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/j.kint.2021.07.013","article-title":"Iron status, fibroblast growth factor 23 and cardiovascular and kidney outcomes in chronic kidney disease","volume":"100","author":"Mehta","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2023.10.005_bib0105","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1093\/qjmed\/hcu045","article-title":"Transferrin saturation ratio and risk of total and cardiovascular mortality in the general population","volume":"107","author":"Stack","year":"2014","journal-title":"QJM"},{"key":"10.1016\/j.nefroe.2023.10.005_bib0110","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1093\/ndt\/gfab050","article-title":"Serum biomarkers of iron stores are associated with worse physical health-related quality of life in nondialysis-dependent chronic kidney disease patients with or without anemia","volume":"36","author":"Guedes","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2023.10.005_bib0115","doi-asserted-by":"crossref","first-page":"e0201662","DOI":"10.1371\/journal.pone.0201662","article-title":"Iron deficiency associates with deterioration in several symptoms independently from hemoglobin level among chronic hemodialysis patients","volume":"13","author":"Motonishi","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.nefroe.2023.10.005_bib0120","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1016\/j.kint.2021.03.020","article-title":"Controversies in optimal anemia management: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) conference","volume":"99","author":"Babitt","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2023.10.005_bib0125","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1056\/NEJMoa1810742","article-title":"Intravenous iron in patients undergoing maintenance hemodialysis","volume":"380","author":"Macdougall","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefroe.2023.10.005_bib0130","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1093\/ndt\/gfu201","article-title":"FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia","volume":"29","author":"Macdougall","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2023.10.005_bib0135","doi-asserted-by":"crossref","first-page":"i15","DOI":"10.1093\/ndt\/gfw123.03","article-title":"So035 The safety of intravenous (Iv) ferric carboxymaltose (Fcm) in patients with non-dialysis dependent Ckd (Nd-Ckd): 1-year results from the find-Ckd trial","volume":"31","author":"Roger","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2023.10.005_bib0140","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1681\/ASN.2018101016","article-title":"A pilot randomized trial of ferric citrate coordination complex for the treatment of advanced CKD","volume":"30","author":"Block","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2023.10.005_bib0145","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s12882-021-02308-y","article-title":"A multicentre prospective double blinded randomised controlled trial of intravenous iron (ferric derisomaltose (FDI)) in iron deficient but not anaemic patients with chronic kidney disease on functional status","volume":"22","author":"Bhandari","year":"2021","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.nefroe.2023.10.005_bib0150","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1093\/ndt\/gft033","article-title":"Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement","volume":"28","author":"Locatelli","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2023.10.005_bib0155","unstructured":"National Institute for Health and Care Excellence. Chronic kidney disease: assessment and management. https:\/\/www.nice.org.uk\/guidance\/ng203; 2021 [Accessed 17 October 2021]."},{"key":"10.1016\/j.nefroe.2023.10.005_bib0160","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.nefroe.2018.01.007","article-title":"Anemia of chronic kidney disease: protocol of study, management and referral to nephrology","volume":"38","author":"Cases","year":"2018","journal-title":"Nefrologia (Engl Ed)"},{"key":"10.1016\/j.nefroe.2023.10.005_bib0165","doi-asserted-by":"crossref","first-page":"575 e3","DOI":"10.1016\/j.ahj.2013.01.017","article-title":"Iron deficiency in chronic heart failure: an international pooled analysis","volume":"165","author":"Klip","year":"2013","journal-title":"Am Heart J"},{"key":"10.1016\/j.nefroe.2023.10.005_bib0170","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1093\/eurheartj\/ehq158","article-title":"Iron deficiency: an ominous sign in patients with systolic chronic heart failure","volume":"31","author":"Jankowska","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.nefroe.2023.10.005_bib0175","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1056\/NEJMoa0908355","article-title":"Ferric carboxymaltose in patients with heart failure and iron deficiency","volume":"361","author":"Anker","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefroe.2023.10.005_bib0180","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/eurheartj\/ehu385","article-title":"Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiencydagger","volume":"36","author":"Ponikowski","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.nefroe.2023.10.005_bib0185","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1161\/CIRCULATIONAHA.117.027497","article-title":"Effect of ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency","volume":"136","author":"van Veldhuisen","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.nefroe.2023.10.005_bib0190","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1016\/S0140-6736(20)32339-4","article-title":"Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial","volume":"396","author":"Ponikowski","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.nefroe.2023.10.005_bib0195","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.hlc.2014.12.161","article-title":"Changes in echocardiographic parameters in iron deficiency patients with heart failure and chronic kidney disease treated with intravenous iron","volume":"24","author":"Toblli","year":"2015","journal-title":"Heart Lung Circ"},{"key":"10.1016\/j.nefroe.2023.10.005_bib0200","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/ehf2.12101","article-title":"Left ventricular ejection fraction recovery in patients with heart failure treated with intravenous iron: a pilot study","volume":"3","author":"Nunez","year":"2016","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.nefroe.2023.10.005_bib0205","doi-asserted-by":"crossref","first-page":"4222","DOI":"10.1002\/ehf2.13053","article-title":"Short-term changes in left and right systolic function following ferric carboxymaltose: a substudy of the Myocardial-IRON trial","volume":"7","author":"Santas","year":"2020","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.nefroe.2023.10.005_bib0210","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.amjcard.2021.04.042","article-title":"Safety and efficacy of intravenous ferric derisomaltose compared to iron sucrose for iron deficiency anemia in patients with chronic kidney disease with and without heart failure","volume":"152","author":"Ambrosy","year":"2021","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.nefroe.2023.10.005_bib0215","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1002\/ejhf.473","article-title":"Effects of intravenous iron therapy in iron-deficient patients with systolic heart failure: a meta-analysis of randomized controlled trials","volume":"18","author":"Jankowska","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.nefroe.2023.10.005_bib0220","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/ejhf.823","article-title":"Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis","volume":"20","author":"Anker","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.nefroe.2023.10.005_bib0225","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1001\/jama.2017.5427","article-title":"Effect of oral iron repletion on exercise capacity in patients with heart failure with reduced ejection fraction and iron deficiency: the IRONOUT HF randomized clinical trial","volume":"317","author":"Lewis","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.nefroe.2023.10.005_bib0230","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/ejhf.592","volume":"18","author":"Ponikowski","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.nefroe.2023.10.005_bib0235","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1093\/ndt\/gfq613","article-title":"A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients","volume":"26","author":"Qunibi","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2023.10.005_bib0240","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1093\/ndt\/gfv293","article-title":"A randomized trial of iron isomaltoside 1000 versus oral iron in non-dialysis-dependent chronic kidney disease patients with anaemia","volume":"31","author":"Kalra","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2023.10.005_bib0245","doi-asserted-by":"crossref","first-page":"301","DOI":"10.5414\/CN109198","article-title":"Erythropoietic response to oral iron in patients with nondialysis-dependent chronic kidney disease in the FIND-CKD trial","volume":"88","author":"Macdougall","year":"2017","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.nefroe.2023.10.005_bib0250","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1053\/j.ajkd.2016.04.018","article-title":"Intravenous versus oral iron supplementation for the treatment of anemia in CKD: an updated systematic review and meta-analysis","volume":"68","author":"Shepshelovich","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nefroe.2023.10.005_bib0255","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/ki.2015.163","article-title":"A randomized trial of intravenous and oral iron in chronic kidney disease","volume":"88","author":"Agarwal","year":"2015","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2023.10.005_bib0260","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/ndt\/gfaa011","article-title":"Safety and efficacy of iron isomaltoside 1000\/ferric derisomaltose versus iron sucrose in patients with chronic kidney disease: the FERWON-NEPHRO randomized, open-label, comparative trial","volume":"36","author":"Bhandari","year":"2020","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2023.10.005_bib0265","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1093\/ndt\/gft251","article-title":"Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: the REPAIR-IDA trial","volume":"29","author":"Onken","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2023.10.005_bib0270","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1038\/ki.2012.270","article-title":"Summary of the KDIGO guideline on anemia and comment: reading between the (guide)line(s)","volume":"82","author":"Drueke","year":"2012","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2023.10.005_bib0275","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1186\/s12882-017-0688-1","article-title":"Renal association clinical practice guideline on Anaemia of Chronic Kidney Disease","volume":"18","author":"Mikhail","year":"2017","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.nefroe.2023.10.005_bib0280","unstructured":"National Institute for Health and Care Excellence: Guidelines. Chronic kidney disease: assessment and management. London: National Institute for Health and Care Excellence (NICE). Copyright \u00a9 NICE 2021; 2021."},{"key":"10.1016\/j.nefroe.2023.10.005_bib0285","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1053\/j.ajkd.2016.05.031","article-title":"Spectrum and burden of erythropoiesis-stimulating agent hyporesponsiveness among contemporary hemodialysis patients","volume":"68","author":"Luo","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nefroe.2023.10.005_bib0290","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1186\/s12882-019-1554-0","article-title":"In search of potential predictors of erythropoiesis-stimulating agents (ESAs) hyporesponsiveness: a population-based study","volume":"20","author":"Ingrasciotta","year":"2019","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.nefroe.2023.10.005_bib0295","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.2215\/CJN.04601007","article-title":"Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients","volume":"3","author":"Kilpatrick","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2023.10.005_bib0300","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1056\/NEJMoa1005109","article-title":"Erythropoietic response and outcomes in kidney disease and type 2 diabetes","volume":"363","author":"Solomon","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefroe.2023.10.005_bib0305","doi-asserted-by":"crossref","first-page":"e0143348","DOI":"10.1371\/journal.pone.0143348","article-title":"Association of erythropoietin-stimulating agent responsiveness with mortality in hemodialysis and peritoneal dialysis patients","volume":"10","author":"Bae","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.nefroe.2023.10.005_bib0310","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/S0272-6386(04)01086-8","article-title":"Epoetin requirements predict mortality in hemodialysis patients","volume":"44","author":"Zhang","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nefroe.2023.10.005_bib0315","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1159\/000358215","article-title":"Erythropoietin resistance index and the all-cause mortality of chronic hemodialysis patients","volume":"37","author":"Okazaki","year":"2014","journal-title":"Blood Purif"},{"key":"10.1016\/j.nefroe.2023.10.005_bib0320","doi-asserted-by":"crossref","first-page":"e004431","DOI":"10.1161\/CIRCHEARTFAILURE.117.004431","article-title":"Hyporesponsiveness to darbepoetin alfa in patients with heart failure and anemia in the RED-HF study (reduction of events by darbepoetin alfa in heart failure): clinical and prognostic associations","volume":"11","author":"van der Meer","year":"2018","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.nefroe.2023.10.005_bib0325","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1159\/000523947","article-title":"Resistance to erythropoiesis-stimulating agents among patients on hemodialysis is typically transient","volume":"53","author":"Goodkin","year":"2022","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.nefroe.2023.10.005_bib0330","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1056\/NEJMoa065485","article-title":"Correction of anemia with epoetin alfa in chronic kidney disease","volume":"355","author":"Singh","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefroe.2023.10.005_bib0335","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/ki.2008.295","article-title":"Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes","volume":"74","author":"Szczech","year":"2008","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2023.10.005_bib0340","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1056\/NEJMoa0907845","article-title":"A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease","volume":"361","author":"Pfeffer","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefroe.2023.10.005_bib0345","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1002\/ejhf.412","article-title":"Increased risk of stroke with darbepoetin alfa in anaemic heart failure patients with diabetes and chronic kidney disease","volume":"17","author":"Bello","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.nefroe.2023.10.005_bib0350","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1093\/ndt\/gfn601","article-title":"Potential mechanisms of adverse outcomes in trials of anemia correction with erythropoietin in chronic kidney disease","volume":"24","author":"Vaziri","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2023.10.005_bib0355","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1111\/j.1399-0012.2005.00428.x","article-title":"Anemia in kidney transplanted patients","volume":"19","author":"Molnar","year":"2005","journal-title":"Clin Transplant"},{"key":"10.1016\/j.nefroe.2023.10.005_bib0360","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1097\/01.tp.0000205174.97275.b5","article-title":"Posttransplantation anemia in adult renal allograft recipients: prevalence and predictors","volume":"81","author":"Shah","year":"2006","journal-title":"Transplantation"},{"key":"10.1016\/j.nefroe.2023.10.005_bib0365","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1034\/j.1600-6143.2003.00133.x","article-title":"Prevalence and management of anemia in renal transplant recipients: a European survey","volume":"3","author":"Vanrenterghem","year":"2003","journal-title":"Am J Transplant"},{"key":"10.1016\/j.nefroe.2023.10.005_bib0370","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1111\/j.1600-6143.2010.03142.x","article-title":"High dose epoetin beta in the first weeks following renal transplantation and delayed graft function: results of the neo-PDGF study","volume":"10","author":"Martinez","year":"2010","journal-title":"Am J Transplant"},{"key":"10.1016\/j.nefroe.2023.10.005_bib0375","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.2215\/CJN.01360212","article-title":"Effect of high-dose erythropoietin on graft function after kidney transplantation: a randomized, double-blind clinical trial","volume":"7","author":"Sureshkumar","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2023.10.005_bib0380","doi-asserted-by":"crossref","first-page":"b4018","DOI":"10.1136\/bmj.b4018","article-title":"Mortality in renal transplant recipients given erythropoietins to increase haemoglobin concentration: cohort study","volume":"339","author":"Heinze","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.nefroe.2023.10.005_bib0385","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1681\/ASN.2011060546","article-title":"Correction of postkidney transplant anemia reduces progression of allograft nephropathy","volume":"23","author":"Choukroun","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2023.10.005_bib0390","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1093\/ndt\/gfy365","article-title":"The effect of maintaining high hemoglobin levels on long-term kidney function in kidney transplant recipients: a randomized controlled trial","volume":"34","author":"Tsujita","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2023.10.005_bib0395","doi-asserted-by":"crossref","first-page":"27","DOI":"10.6002\/ect.2018.0283","article-title":"Treating posttransplant anemia with erythropoietin improves quality of life but does not affect progression of chronic kidney disease","volume":"18","author":"Pile","year":"2020","journal-title":"Exp Clin Transplant"},{"key":"10.1016\/j.nefroe.2023.10.005_bib0400","doi-asserted-by":"crossref","first-page":"E636","DOI":"10.1111\/ctr.12220","article-title":"Anemia is a predictor of graft loss but not cardiovascular events and all-cause mortality in renal transplant recipients: follow-up data from the ALERT study","volume":"27","author":"Schjelderup","year":"2013","journal-title":"Clin Transplant"},{"key":"10.1016\/j.nefroe.2023.10.005_bib0405","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1101\/gad.1243304","article-title":"The biology of hypoxia: the role of oxygen sensing in development, normal function, and disease","volume":"18","author":"Giaccia","year":"2004","journal-title":"Genes Dev"},{"key":"10.1016\/j.nefroe.2023.10.005_bib0410","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1152\/physrev.00030.2011","article-title":"Adaptive and maladaptive cardiorespiratory responses to continuous and intermittent hypoxia mediated by hypoxia-inducible factors 1 and 2","volume":"92","author":"Prabhakar","year":"2012","journal-title":"Physiol Rev"},{"key":"10.1016\/j.nefroe.2023.10.005_bib0415","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1111\/jcpt.13385","article-title":"Long-term efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitors in anaemia of chronic kidney disease: a meta-analysis including 13,146 patients","volume":"46","author":"Chen","year":"2021","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.nefroe.2023.10.005_bib0420","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1056\/NEJMoa2025956","article-title":"Safety and efficacy of vadadustat for anemia in patients undergoing dialysis","volume":"384","author":"Eckardt","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefroe.2023.10.005_bib0425","doi-asserted-by":"crossref","unstructured":"Carol A. Pollock, Simon Roger, Roberto Manllo-Karim, Maksym Pola, Stefan Tham, Kin-Hung P Yu, MD and Mohamed El-Shahawy. Roxadustat increases hemoglobin in anemic Non-Dialysis-Dependent (NDD) Chronic Kidney Disease (CKD) patients independent of inflammation. 62nd ASH Annual Meeting and Exposition, 2020.","DOI":"10.1681\/ASN.20203110S1132c"},{"key":"10.1016\/j.nefroe.2023.10.005_bib0430","unstructured":"Volker H. Haase, Bruce S. Spinowitz, Pablo E. Pergola, Zeeshan Khawaja, Qing Zuraw, Amit Sharma, et al. Efficacy and Dose Requirements of Vadadustat Are Independent of Systemic Inflammation and Prior Erythropoiesis-Stimulating Agent (ESA) Dose in Patients With Non-Dialysis Dependent Chronic Kidney Disease (NDD-CKD). ASN KIDNEY WEEK 2016."},{"author":"EMA","key":"10.1016\/j.nefroe.2023.10.005_bib0435"},{"key":"10.1016\/j.nefroe.2023.10.005_bib0440","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1056\/NEJMoa2035938","article-title":"Vadadustat in patients with anemia and non-dialysis-dependent CKD","volume":"384","author":"Chertow","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefroe.2023.10.005_bib0445","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1056\/NEJMoa2113380","article-title":"Daprodustat for the treatment of anemia in patients not undergoing dialysis","volume":"385","author":"Singh","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefroe.2023.10.005_bib0450","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1056\/NEJMoa2113379","article-title":"Daprodustat for the treatment of anemia in patients undergoing dialysis","volume":"385","author":"Singh","year":"2021","journal-title":"N Engl J Med"}],"container-title":["Nefrolog\u00eda (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2013251423001645?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2013251423001645?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T19:51:27Z","timestamp":1761853887000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2013251423001645"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":90,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S2013251423001645"],"URL":"https:\/\/doi.org\/10.1016\/j.nefroe.2023.10.005","relation":{},"ISSN":["2013-2514"],"issn-type":[{"type":"print","value":"2013-2514"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Unresolved aspects in the management of renal anemia, a Delphi consensus of the Anemia Group of the S.E.N","name":"articletitle","label":"Article Title"},{"value":"Nefrolog\u00eda (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nefroe.2023.10.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.nefro.2022.11.009","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Sociedad Espa\u00f1ola de Nefrolog\u00eda. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}